[_bin_]

Okay, I looked at Baggott's work a little more. Here are my primary concerns:

1. He's talking his book to a certain extent. This is his life's work and he runs a company in this space (though a B corp) so he will have a bias here. That's fine overall, as it may help balance people unfairly biased against psychedelics, but it's worth remembering. I'm not saying this to impugn his character so much as to point out everyone has biases, and someone in his position likely has strong ones, even if partially-founded.

2. He believes an SSRI alleviates negative symptoms, but we don't know it does more than alleviate the comedown. It appears his endpoint was cognitive performance post-use, not long-term damage that may appear once off the SSRI.

3. This doesn't touch the dopaminergic risks of amphetamines, which are substantial.

A few exploratory bits of research into one potential way to alleviate the acute effects post-administration don't translate to an established method to use this in a remotely-safe fashion.